A group based on complementary expertise with multidisciplinary know-how

A range of integrated biotechnology solutions

A complete platform, from DNA to recombinant antibodies

News

Biotech Investissement Holding sells its affiliate Diaclone SAS (France) to Medix Biochemica (Finland)

Date of publication : 15/07/2021

Biotech Investissement will reinforce its business in the biomanufacturing market and molecular engineering services and sells its affiliate Diaclone SAS to Medix Biochemica. The arrival of Diaclone into Medix Biochemica group will give Diaclone access to new international market and then allow to continue its fantastic growth on the IVD market.

 

  • Medix Biochemica is an international group, leader on the IVD market with raw material supply worldwide. By incorporation of Diaclone in Medix, Diaclone will have access to Marketing team and to the customer basis of Medix specially on new territories like Asia and USA.
  • Biotech Investissement will continue actively its close collaboration with Diaclone through its affiliate RD-Biotech, concerning biomanufacturing.
  • Biotech Investissement will now focus its business in biomanufacturing capacities (plasmids DNA, monoclonal antibodies and recombinant proteins) and will start soon a new business unit exclusively dedicated to « GMP grade » plasmid DNA manufacturing (RD-Biotech, Besançon - France).

 

« Following careful consideration, we concluded that it is the right time to find a new partner to support Diaclone’s future international growth. We are convinced that Medix Biochemica with its comprehensive reach to IVD customers globally, strong focus on quality and R&D and clear long-term vision, is the optimal new partner for Diaclone”, says Philippe Dulieu, President of Biotech Investissement Group and RD-Biotech.

 

“The acquisition of Diaclone is an important step towards our vision to be the first-choice, independent raw material partner for the IVD industry. The portfolio of Diaclone, including several gold standard antibodies, complements the offering of Medix Biochemica very well, and we are excited about the opportunity to offer these products to our global customer base. In addition, we see an excellent strategic and cultural fit with Medix Biochemica, and we value Diaclone’s technical and scientific competence highly. We look forward to jointly developing innovative and high-quality products to support our customers even better in the future”, says Steve Ferguson, CEO of Medix Biochemica.

 

Biotech Investissement

The Biotech Investissement group (BI) was founded in 2012 in Besançon (France) by Philippe Dulieu, founder of RD-BIOTECH, a renowned French CRO. Biotech Investissement had acquired Diaclone in 2012 to Hologics Gen-probe (USA). BI is actively involved as shareholder in different biotech companies in France and across Europe.

 

Through its brand mAbexperts, Biotech Investissement is now a key player on the market of molecular biology, antibody engineering concerning preclinical, clinical research, and biomanufacturing.

 

More information

Philippe Dulieu, CEO

Biotech Investissement

Tel: +33 (0)3 81 53 88 37

Email: info@rd-biotech.com

www.mabexperts.com

  • Custom antibody biomanufacturing & Autumn discounts
    Date of publication : 13/09/2021
    Contact us for more information! Read more
  • RD-Biotech will participate to the first edition of the Innovative Therapies Days, on October 14 and 15, 2021 in Besancon
    Date of publication : 09/09/2021

    First edition of Innovative Therapies Days on 14 and 15 October 2021 in Besancon (25-France) organized by Innov'Health! The meeting of local and international companies specialized in...

    Read more
  • A new website for RD-Biotech
    Date of publication : 23/08/2021

    We are pleased to inform you that RD-Biotech has launched a brand-new website!

    Find here all of the custom development and biomanufacturing services for plasmids, antibodies, recombinant proteins...

    Read more
  • Biotech Investissement Holding sells its affiliate Diaclone SAS (France) to Medix Biochemica (Finland)
    Date of publication : 15/07/2021

    Biotech Investissement will reinforce its business in the biomanufacturing market and molecular engineering services and sells its affiliate Diaclone SAS to Medix Biochemica. The arrival of Diaclone...

    Read more
  • Now Available! Recombinant Human SARS-CoV-2 Spike RBD Variant Lineage B.1.617, India (HEK)
    Date of publication : 19/05/2021
  • Diaclone ELISpot assays, tried and trusted by researchers worldwide
    Date of publication : 01/04/2021


    Diaclone ELISpots (Enzyme-Linked Immunospot Assays) are highly specific immunoassays for the analysis of cytokine and other soluble molecule production and secretion from T-cells at a single cell...

    Read more
  • Come and join our team!
    Date of publication : 11/03/2021

    As part of the development of its new GMP plasmid production unit, RD-Biotech is recruiting two new profiles:

    - Technician in Molecular Biology Bioproduction

    - Quality Control Manager

    For...

    Read more
  • Diaclone is a partner in a major European project involving a dozen partners from the Besançon region.
    Date of publication : 21/08/2018

    Le Projet MiMédi

    MIMEDI: MIcrotechnique pour les MEDicaments Innovants nouvelles solutions technologiques pour optimiser la fabrication de "cellules médicaments"

    Au sein...

    Read more